Viatris Announces Approval of WAKIX® (Pitolisant) in Japan, a First-in-Class Treatment for Narcolepsy and Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea Syndrome

Approval Addresses High Unmet Medical Need and Further Advances Viatris' Innovative Portfolio in Japan PITTSBURGH, Sept. 16, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that Japan's Ministry of Health, Labour and Welfare has granted approval for WAKIX® (pitolisant) for the treatment of excessive daytime sleepiness (EDS) associated with obstructive sleep apnea syndrome (OSAS) in patients receiving treatment for airway obstruction, and approval for narcolepsy (type 1 and 2 – with and without cataplexy).

PRNewsWire • Sep 16, 2026

Viatris (VTRS) is a Top-Ranked Value Stock: Should You Buy?

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Investment Research • Sep 9, 2026

Viatris: Strong Cash Generation And Pipeline Progress Keep The Re-Rating Story Alive

Viatris' Q2 showed better earnings quality, with adjusted net income and EPS up 11% while free cash flow doubled year-over-year. Deleveraging remains on track, while buybacks and dividends demonstrate that stronger cash generation is already supporting shareholder returns. Pipeline progress and new-product approvals provide additional growth optionality beyond the mature portfolio, with key Phase 3 assets approaching important milestones.

Seeking Alpha • Sep 9, 2026

17 Ideal 'Safer' Buyable August Dogs Dug Up After 10 Years

I analyze 89 top Ten-Year Collected Dividend Dogs, focusing on yield-based strategies and safety via free cash flow coverage. Ten-year top dividend dogs project average net gains of 39.61% by August 2027, with risk profiles generally below market volatility. Seventeen 'safer' dogs meet the ideal of annual dividends from $1K invested exceeding share price, signaling strong income potential.

Seeking Alpha • Aug 28, 2026

3 Generic Drug Stocks to Watch Amid Improving Industry Trends

The Medical - Generic Drugs industry gains from new launches, biosimilar momentum and portfolio shifts, despite pricing pressure and supply challenges.

Zacks Investment Research • Aug 27, 2026

Here's Why Viatris (VTRS) is a Strong Value Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Investment Research • Aug 18, 2026

Compared to Estimates, Viatris (VTRS) Q2 Earnings: A Look at Key Metrics

Although the revenue and EPS for Viatris (VTRS) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Investment Research • Aug 6, 2026

VTRS Q2 Earnings Beat, Revenues Rise 5% as Greater China Sales Jump

Viatris tops Q2 earnings and revenue estimates as Greater China sales surge 21%, helping lift results and prompting a higher 2026 financial outlook.

Zacks Investment Research • Aug 6, 2026

Viatris Inc. (VTRS) Q2 2026 Earnings Call Transcript

Viatris Inc. (VTRS) Q2 2026 Earnings Call Transcript

Seeking Alpha • Aug 6, 2026

Viatris Reports Second-Quarter 2026 Financial Results

Delivers Total Revenues of $3.8 Billion, Representing 5% Reported Growth Compared to Second Quarter 2025 and a U.S. GAAP Net Loss of $119 Million Total Revenues Were Up 3.5% Operationally Compared to Second Quarter 2025 Adjusted EBITDA was $1.2 Billion, Up 8% Operationally Compared to Second Quarter 2025 Advances Key Pipeline Milestones, Including U.S. FDA Approval of Gwyn LoTM Announces Sale of Global Rights to Tyrvaya® Returns Approximately $550 Million of Capital to Shareholders, Including Through Share Repurchases; Reduces Gross Leverage Ratio to 2.9x Raises 2026 Financial Guidance Midpoints for All Metrics [1] PITTSBURGH, Aug. 6, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced its second-quarter 2026 financial results. Executive Commentary "Our second-quarter results reflect another quarter of strong execution and reinforce the momentum we're building across our business," said Scott A.

PRNewsWire • Aug 6, 2026